Protagonist Therapeutics, Inc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Protagonist Therapeutics, Inc (PTGX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 4.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-25
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 4.90%.
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -1.70%, a 950.00% decline from fiscal 2023.
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 0.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | 4.90% 10-K · filed 2026-02-25 |
| 2024-12-31 | -1.70% 10-K · filed 2026-02-25 |
| 2023-12-31 | 0.20% 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |